End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
100,100 KRW | +0.10% | +4.27% | +47.64% |
2023 | ST Pharm Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
2021 | ST Pharm Co.,Ltd. Announces Expansion of Oligonucleotide Facility | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 49.51 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+47.64% | 1.39B | - | ||
+37.78% | 723B | C+ | ||
+31.60% | 598B | B | ||
-3.51% | 364B | C+ | ||
+19.94% | 331B | B- | ||
+5.14% | 288B | C+ | ||
+16.53% | 244B | B+ | ||
-4.42% | 208B | A+ | ||
+10.26% | 210B | B- | ||
+9.32% | 169B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A237690 Stock
- Ratings ST Pharm Co.,Ltd.